What is Fennec Pharmaceuticals Inc.'s (FENC) StockRank?

MoatMap's StockRank for Fennec Pharmaceuticals Inc. (FENC) is 57/100, with a Hold signal. This is a composite score combining Quality (55), Value (23), and Momentum (74) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Fennec Pharmaceuticals Inc. have an economic moat?

Fennec Pharmaceuticals Inc. (FENC) has a Quality factor score of 55/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Fennec Pharmaceuticals Inc. a buy, hold, or sell?

MoatMap's current signal for Fennec Pharmaceuticals Inc. (FENC) is Hold, based on a StockRank of 57/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Fennec Pharmaceuticals Inc. in?

Fennec Pharmaceuticals Inc. (FENC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

FENC

HoldPremium Grower

Fennec Pharmaceuticals Inc. · Healthcare · United States · $430M · Avg Vol: $3M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-18.6%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

Fennec Pharmaceuticals is a specialty pharmaceutical company focused on oncology supportive care. Its lead product, PEDMARK (sodium thiosulfate), is the first and only FDA-approved therapy to reduce the risk of ototoxicity associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors. The company occupies a critical niche addressing an unmet medical need in pediatric cancer care.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	1.5M	21.3M	47.5M	44.6M	207.5%	59.2M	72.9M	103.2M	52.0%
EPS	-0.90	-0.60	0.00	-0.35	—	-0.12	—	—	—
Shares	26.4M	27.0M	27.5M	34.2M	+29.6%	35.1M	—	—	—
Debt	24.9M	31.0M	19.3M	0	-11.9%	—	—	—	—
Equity	-2.6M	-11.6M	-5.9M	35.5M	—	—	—	—	—
Op CF	-18.1M	-17.1M	27.0M	-12.5M	—	-2.0M	—	—	—
Inv CF	—	—	—	—	—	—	—	—	—
Fin CF	20.7M	6.6M	-13.6M	22.6M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)+14.0%

SMA 50SMA 200

$11.30

RSI (14)

49.4

52W High

$13.25

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-11.3%34.0

ROE

-18.6%30.8

GP/Assets

78.7%96.0

Op. Margin

9.7%62.0

FCF/Assets

n/mN/A

Piotroski

00.1

Int. Cover

-4.5x27.7

D/E Ratio

0.00x98.1

Current Ratio

5.85x76.5

Value

P/E (TTM)

—N/A

EV/EBITDA

-385.0x25.0

P/FCF

n/mN/A

P/B

10.2x11.7

P/S

7.3x31.9

Div Yield

—N/A

Momentum

52W High %

85%78.8

RS 6M

29%85.5

SMA 50/200

1.27x92.2

EPS Rev 4W

+7.0%86.2

EPS Rev 12W

-7.3%15.0

EPS Improve

+893%97.8

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$430M

P/E (Forward)

13.0x

Gross Margin

93.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FENC are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
FENC	Fennec Pharmaceuticals Inc.(you)	$430M	57	Hold
ANL	Adlai Nortye Group Ltd.	$890M	51	Hold
MNPR	Monopar Therapeutics Inc.	$751M	47	Hold
AGEN	Agenus Inc.	$345M	75	Buy
ARVN	Arvinas, Inc.	$592M	40	Hold
MDXG	MiMedx Group, Inc.	$656M	73	Buy
ABEO	Abeona Therapeutics Inc.	$339M	37	Hold
ARTV	Artiva Biotherapeutics, Inc.	$542M	36	Hold
OABI	OmniAb, Inc.	$650M	38	Hold
OVID	Ovid Therapeutics Inc.	$547M	34	Sell

Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.1%

Fennec Pharmaceuticals Inc. (FENC): Stock Score Summary

Fennec Pharmaceuticals Inc. (FENC) has a MoatMap StockRank of 57/100 based on Quality (55/100), Value (23/100), and Momentum (74/100) factor scores. The current signal is HOLD.

Key Financial Metrics

Price	$11.30
Market Cap	$430M
P/E (Forward)	13.01
Price/Book	10.23
Return on Equity	-18.6%
Return on Invested Capital	-11.3%
Debt/Equity	0.00x
Gross Margin	93.7%
Operating Margin	9.7%
Revenue Growth	85.2%
Free Cash Flow	$1M

Fennec Pharmaceuticals Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Fennec Pharmaceuticals Inc.’s (FENC) StockRank?: MoatMap’s StockRank for Fennec Pharmaceuticals Inc. (FENC) is 57/100, with a Hold signal. It is a composite of Quality (55), Value (23), and Momentum (74) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Fennec Pharmaceuticals Inc. have an economic moat?: Fennec Pharmaceuticals Inc. (FENC) has a Quality factor score of 55/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Fennec Pharmaceuticals Inc. a buy, hold, or sell?: MoatMap’s current signal for Fennec Pharmaceuticals Inc. (FENC) is Hold, based on a StockRank of 57/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Fennec Pharmaceuticals Inc. in?: Fennec Pharmaceuticals Inc. (FENC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).